IP Library Granted Patent US 10,343,979
Granted Patent B2
US 10,343,979 · App. 15/527,811 · Granted Jul 9, 2019

Methods of manufacturing treprostinil and treprostinil derivative prodrugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,343,979
App. No.
15/527,811
Granted
Jul 9, 2019
Kind
B2
Abstract

Methods for making prodrugs of trepreostinil and treprostinil derivatives are provided. Specifically, methods are provided herein for producing prostacyclin compounds comprising treprostinil covalently linked to a linear C 5 -C 18 alkyl, branched C 5 -C 18 alkyl, linear C 2 -C 18 alkenyl, branched C 3 -C 18 alkenyl, aryl, aryl-C 1 -C 18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide). The linkage, in one embodiment, is via an amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. The compounds provided herein can be used to treat pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension.

Claims (11)

1. A method for making a treprostinil prodrug having the following formula:

comprising,

mixing, in the presence of an acid catalyst, treprostinil with an alcohol of the formula R 2 —OH, wherein R 2 is a linear or branched C 5 -C 18 alkyl, a linear C 2 -C 18 alkenyl or a branched C 3 -C 18 alkenyl, aryl, aryl-C 1 -C 18 alkyl, an amino acid or a peptide,

incubating the mixture for a sufficient period of time to form the compound of Formula (A).

2. The method of claim 1 , wherein treprostinil is dissolved in a solvent prior to mixing with the acid catalyst.

3. The method of claim 2 , wherein the solvent comprises dioxane.

4. The method of claim 2 , wherein the solvent comprises acetonitrile (MeCN), N,N′-dimethylformamide (DMF), dichloromethane (DCM), or a combination thereof.

5. The method of claim 2 , wherein the solvent comprises 2 mL of dioxane per 100 μmol of treprostinil, 1 mL of dioxane per 100 μmol of treprostinil, DMF, DCM, MeCN, 1:1 dioxane:MeCN, DMF/DCM, 10% DMF/DCM, or 20% DMF/DCM.

6. The method of claim 1 , wherein the acid catalyst is a solid.

7. The method of claim 6 , wherein the solid is a solid resin.

8. The method of claim 1 , wherein the acid catalyst comprises sulfuric acid, sulfonic acid, hydrofluoric acid, phosphoric acid, toluenesulfonic acid, polystyrene solfonate, hyeteropoly acid, zeolites, metal oxides, graphene oxygene or a combination thereof.

Assignments (3)
PATENT SECURITY AGREEMENT Recorded Oct 20, 2022
From: INSMED INCORPORATED
To: BIOPHARMA CREDIT PLC
Reel/Frame 061735/0875 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded Oct 19, 2022
From: INSMED INCORPORATED
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 061727/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2017
From: MALININ, VLADIMIR; PERKINS, WALTER; LEIFER, FRANZISKA; KONICEK, DONNA M.; LI, ZHILI; PLAUNT, ADAM
To: INSMED INCORPORATED
Reel/Frame 043858/0988 →
Cited By (1)
US 12,697,315